Teladoc Faces Pressure Over Capital Allocation And Stock Underperformance

Benzinga_recent_news04-02

The investment advisor, which holds a stake in Teladoc through Pineal Capital Fund 1, said it has engaged with management for months but remains concerned about the board's slow pace of action on ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624660510?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/01/Doctor-Looking-At-Human-Teeth-X-ray.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-02 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624660510","market":"hk","top_or_hot":-1,"title":"Teladoc Faces Pressure Over Capital Allocation And Stock Underperformance","media":"Benzinga_recent_news","content":"<div>\n<p>The investment advisor, which holds a stake in Teladoc through Pineal Capital Fund 1, said it has engaged with management for months but remains concerned about the board's slow pace of action on ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/04/51604464/teladoc-faces-pressure-over-capital-allocation-and-stock-underperformance\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Faces Pressure Over Capital Allocation And Stock Underperformance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Faces Pressure Over Capital Allocation And Stock Underperformance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 00:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/26/04/51604464/teladoc-faces-pressure-over-capital-allocation-and-stock-underperformance><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The investment advisor, which holds a stake in Teladoc through Pineal Capital Fund 1, said it has engaged with management for months but remains concerned about the board's slow pace of action on ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/04/51604464/teladoc-faces-pressure-over-capital-allocation-and-stock-underperformance\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TDOC","symbol_name":"Teladoc Health Inc.","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/26/04/51604464/teladoc-faces-pressure-over-capital-allocation-and-stock-underperformance","article_id":"2624660510","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/01/Doctor-Looking-At-Human-Teeth-X-ray.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/04/51604464/teladoc-faces-pressure-over-capital-allocation-and-stock-underperformance","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624660510","pubTimestamp":1775059200,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Pineal Capital urges Teladoc to boost buybacks, cut costs, and review strategy amid concerns over valuation and takeover risk.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"TDOC":"Teladoc Health Inc."},"translate_title":"Teladoc面临资本配置和股票表现不佳的压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TDOC":1.5},"content_text":"The investment advisor, which holds a stake in Teladoc through Pineal Capital Fund 1, said it has engaged with management for months but remains concerned about the board's slow pace of action on critical strategic issues.\nPineal argues that Teladoc's current market price significantly undervalues its long-term growth prospects, despite its leadership position in virtual healthcare and a member base exceeding 100 million users globally.\nBenzinga reached out to Teladoc for comment on the Pineal Capital letter but did not receive a response at the time of publication.\nThe firm highlighted a series of missteps that have weighed on investor confidence, including past acquisitions and capital allocation decisions.\nIt specifically pointed to the 2020 Livongo acquisition, which it described as overvalued and poorly timed, questioning the decision to partially fund the deal with debt despite a strong equity valuation at the time.\nThe investor further criticized the absence of share buybacks, arguing that Teladoc has failed to act despite a significantly undervalued stock and an under-levered balance sheet.\nTeladoc shares have declined more than 90% from pre-COVID highs, even as the company strengthened its competitive positioning.\nPineal said the lack of a clearly articulated multi-year strategy, including limited investor communication and no recent Investor Day, has added to market uncertainty.\nThe firm also flagged ongoing equity dilution from stock-based compensation, noting that shares outstanding have nearly doubled since 2020 without offsetting buybacks.\nPineal outlined a three-part plan to improve performance, including cost reductions, a $200 million-plus share repurchase program, and a full strategic review.\nThe review could include separating Teladoc's Integrated Care and BetterHelp segments, which Pineal believes would eliminate a \"conglomerate discount\" and unlock value.\nDespite its criticisms, Pineal emphasized strong underlying fundamentals, including favorable policy changes, the rollout of a 24/7 virtual care platform, and growth in BetterHelp's insurance-based model.\nThe firm also identified Teladoc's mental health segment as a \"hidden crown jewel,\" citing over $1.1 billion in related revenue in 2025 and significant long-term growth potential.\nIt added that recent valuation multiples in comparable transactions, such as Talkspace, further highlight the disconnect between Teladoc's current valuation and its intrinsic worth.\nIn February, Teladoc Health reported a quarterly loss of 14 cents per share, which was better than the consensus loss of 18 cents.\nAdditionally, sales increased to $642.27 million, surpassing the expected $635.24 million, driven by a 24% rise in other revenue streams, although access fees revenue fell by 4%.\nTeladoc Health expects the first quarter 2026 loss to be between 35-45 cents compared to the consensus loss of 25 cents, with sales of $598-$620 million versus the consensus of $633.75 million.\nThe telehealth company sees a fiscal 2026 loss of 70 cents to $1.10, with sales of $2.47 billion to $2.59 billion, compared to the consensus of 76 cents and $2.55 billion, respectively.\nTDOC Stock Price Activity: Teladoc Health shares were down 0.64% at $5.52 at the time of publication on Wednesday, according to Benzinga Pro data.\nImage via Teladoc\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624660510","isCrawlerRequest":true}